Christos Adamopoulos

Dr. Christos Adamopoulos

Biological Chemistry, Medicine School, National and Kapodistrian University of Athens, Athens, Attikí, Greece
+1
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Circulation
Verified
Journal Article
Open access
PDF file
EKEva Kassi
Eva Kassi
Christos AdamopoulosChristos Adamopoulos
Christos Adamopoulos
EBEfthimia K. Basdra
Efthimia K. Basdra
Athanasios G. PapavassiliouAthanasios G. Papavassiliou
Athanasios G. Papavassiliou

1 January 2019 in Cell Reports
Verified
Journal Article
Open access
TATamer A. Ahmed
Tamer A. Ahmed
Christos AdamopoulosChristos Adamopoulos
Christos Adamopoulos
ZKZoi Karoulia
Zoi Karoulia
XWXuewei Wu
Xuewei Wu
RSRavi Sachidanandam
Ravi Sachidanandam
PPPoulikos I. Poulikakos
Poulikos I. Poulikakos
Pharmacologic targeting of components of ERK signaling in ERK-dependent tumors is often limited by adaptive resistance, frequently mediated by feedback-activation of RTK signaling and rebound of ERK activity. Here, we show that combinatorial pharmacologic targeting of ERK signaling and the SHP2 phosphatase prevents adaptive resistance in defined subsets of ERK-dependent tumors. In each tumor that was sensitive to combined treatment, p(Y542)SHP2 induction was observed in response to ERK signaling inhibition. The strategy was broadly effective in TNBC models and tumors with RAS mutations at G12, whereas tumors with RAS(G13D) or RAS(Q61X) mutations were resistant. In addition, we identified a subset of BRAF(V600E) tumors that were resistant to the combined treatment, in which FGFR was found to drive feedback-induced RAS activation, independently of SHP2. Thus, we identify molecular determinants of response to combined ERK signaling and SHP2 inhibition in ERK-dependent tumors.

1 July 2012 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
Christina PiperiChristina Piperi
Christina Piperi
Christos AdamopoulosChristos Adamopoulos
Christos Adamopoulos
GDGeorgia Dalagiorgou
Georgia Dalagiorgou
EDEvanthia Diamanti-Kandarakis
Evanthia Diamanti-Kandarakis
Athanasios G. PapavassiliouAthanasios G. Papavassiliou
Athanasios G. Papavassiliou
Context: Advanced glycation, the major posttranslational modification of proteins, DNA, and lipids, is accelerated under conditions of increased oxidative stress, hyperglycemia, and hypoxia contributing to a variety of metabolic diseases such as diabetes mellitus, obesity, inflammation, polycystic ovarian syndrome, ischemic cardiovascular disease, and neurodegenerative disorders. The potential role of advanced glycation in endoplasmic reticulum (ER) homeostasis is largely unknown. Evidence Acquisition: Basic and clinical peer-reviewed articles on advanced glycation and ER stress related to metabolic regulation were searched in PubMed from 2000–2011. The resulting articles as well as relevant cited references were reviewed. Evidence Synthesis: Recent evidence indicates that hyperglycemia, hypoxia, and oxidative stress, apart of triggering advanced glycation, can also adversely affect ER function, leading to pathogenic ER stress, followed by the unfolded protein response. The concomitant presence of advanced glycation in the same conditions with ER stress suggests their crosstalk in the progression of diseases associated with hypoxic and oxidative stress. Conclusion: Current data support the direct or indirect induction of ER stress response by advanced glycation end products or advanced glycation end product precursors in the pathogenesis of metabolic diseases. Inhibitors of advanced glycation acting as potent ER stress modulators with beneficial effects in restoring ER homeostasis and adjusting physiological unfolded protein response level present an emerging therapeutic approach with significant applications, especially in the context of metabolic dysfunction.

1 March 2016 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
Christina PiperiChristina Piperi
Christina Piperi
Christos AdamopoulosChristos Adamopoulos
Christos Adamopoulos
Athanasios G. PapavassiliouAthanasios G. Papavassiliou
Athanasios G. Papavassiliou

8 December 2015 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
Christos AdamopoulosChristos Adamopoulos
Christos Adamopoulos
Christina PiperiChristina Piperi
Christina Piperi
AGAntonios N. Gargalionis
Antonios N. Gargalionis
GDGeorgia Dalagiorgou
Georgia Dalagiorgou
ESEliana Spilioti
Eliana Spilioti
Athanasios G. PapavassiliouAthanasios G. Papavassiliou
Athanasios G. Papavassiliou

13 August 2013 in NeuroMolecular Medicine
Verified
Journal Article
Closed access
PDF file
ASAnastasia Spyropoulou
Anastasia Spyropoulou
AGAntonios Gargalionis
Antonios Gargalionis
GDGeorgia Dalagiorgou
Georgia Dalagiorgou
Christos AdamopoulosChristos Adamopoulos
Christos Adamopoulos
KPKostas A. Papavassiliou
Kostas A. Papavassiliou
Athanasios G. PapavassiliouAthanasios G. Papavassiliou
Athanasios G. Papavassiliou